ABSTRACT Recombinant soluble CD4 (rsCD4) has potent antiviral activity against cell line-adapted isolates of the human immunodeficiency virus type 1 (iHV-1) but low activity toward H1V-1 primary isolates from patients. A simple hypothesis proposed to explain this discrepancy, which questions the therapeutic utility of soluble CD4-based approaches, is that the major envelope glycoprotein, gpl20, of patient virus has lower
affinity for CD4 than does gpl20 from laboratory viruses. To test this hypothesis, we have produced pairs of low-and high-passage HIV-1 isolates which, depending on culture passage history, display dramatically different sensitivities to neutralization by rsCD4. Here, we present evidence that the HIV-1 major envelope glycoprotein cDNAs cloned from one such isolate pair show only minor differences in their deduced gpl20 primary structures, and these occur outside regions previously shown to be involved in CD4 interactions. In addition, recombinant gpl20 from a low-passage rsCD4-resistant patient virus binds rsCD4 with high affinity, equal to that previously measured for recombinant gpl20 from highpassage cell line-adapted virus isolates. These data indicate that differences in CD4-gp12O affinity do not account for rsCD4 resistance in HIV-1 recently isolated from patients.
The antiviral activities in vitro of recombinant soluble versions of CD4, the primary cell surface receptor for human immunodeficiency virus type 1 (HIV-1), have been extensively documented (reviewed in refs. 1 and 2). A number of soluble CD4 congeners have been shown to block laboratory isolates of HIV-1, generated after prolonged passage in tumor cell lines, in both replication assays and HIV-induced syncytium assays. The concentration of recombinant soluble CD4 (rsCD4) required to neutralize such laboratory isolates of HIV-1 appears to depend on the dissociation constant (Kd) for the complex of CD4 and the virus major envelope glycoprotein, gpl20. For example, replication of cell lineadapted viruses such as HIV-1/IIIB and HIV-1/RF, Kd(gpl2O/CD4) = 1-5 nM, typically is blocked by rsCD4 at concentrations less than 20 nM (1, 3) . However, cell lineadapted isolates of retroviruses such as HIV-2 and simian immunodeficiency virus of macaque monkeys (SIVmac), which also utilize CD4 as a cellular receptor, express envelopes with lower affinity for human CD4 and require commensurately higher concentrations of rsCD4 to block virus replication. For example, HIV-2, Kd(gpl2O/CD4) = 48 nM, requires more than 100 nM rsCD4 for complete blocking (4, 5) , while SIVmac, Kd(envelope/CD4) = 350 nM (6) , requires more than 2 ,uM rsCD4 to achieve total blocking (4, 7) . The correlation between intrinsic CD4-gpl20 affinity and the concentration of rsCD4 required to block virus replication supports the model that rsCD4 neutralizes HIV-1 by coating the virus envelope, competing with cellular CD4 (1, 8, 9) .
A striking difference in relative sensitivity to rsCD4-mediated neutralization has been uncovered by comparing the level of rsCD4 required to inhibit replication of common HIV-1 cell line-adapted isolates and that needed to block HIV-1 in patient plasma, from patient peripheral blood mononuclear cells (PBMCs) grown in vitro, or produced after one or a few passages in vitro. Such primary, or low-passage, HIV-1 isolates require 100-to 1000-fold higher concentrations of rsCD4 to block virus replication in vitro (10) . Considering the range of envelope-CD4 affinities described above, an obvious hypothesis for the relative rsCD4 resistance of low-passage HIV-1 is that gp120s from primary isolates have relatively low affinity for CD4, as suggested by Daar et al. (10) . We have tested this hypothesis by isolating pairs (each pair from independent AIDS patient blood samples) of low-passage rsCD4-resistant and high-passage rsCD4-sensitive HIV-1 and by comparing them with respect to proviral gpl20 nucleotide sequence and CD4 binding of the corresponding recombinant gpl20s (r-gpl20s). Data from these analyses suggest that gp120 affinity for CD4 does not change during HIV-1 passage on cell lines and that other mechanisms must be invoked to explain the relative rsCD4 resistance of primary HIV-1 isolates.
MATERIALS AND METHODS
Virus and Cell Culture. Except where noted, culture methods and media have been described (11, 12) . HIV-1/IIIB (a gift ofM. Popovic and R. Gallo, National Institutes of Health) was propagated as described (11) . The primary HIV-1 isolates lymphocytotropic JR-CSF and dual mono-and lymphocytotropic JR-FL (13) were supplied by the National Institutes of Health AIDS Research and Reagent Program. Clinical blood specimens, provided by the Massachusetts General Hospital AIDS clinic, were processed for plasma and PBMC isolations, and primary cultures were grown in R-20 (RPMI-1640 medium with 20% fetal calf serum) supplemented with interleukin 2 essentially as described (12, 14) . Primary (i.e., minimally passaged) isolates of HIV-1 were produced by cocultivation of patient plasma or patient PBMCs with pooled PBMCs from seronegative donors (Leukopack; American Red Cross) that had been activated with phytohemagglutinin (PHA) (designated as PBMC.PHA) (12) . Primary isolates in these studies are designated with the letter P. followed by a patient number. For example, primary Abbreviations: HIV, human immunodeficiency virus; HIV-1 and HIV-2, HIV types 1 and 2; rsCD4, recombinant soluble CD4; r-gpl20, recombinant gpl20; PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin; TCID, tissue culture infectious dose; HRP, horseradish peroxidase. §To whom reprint requests should be addressed.
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isolates P-17 and P-08, derived from PBMCs ofpatient 17 and patient 08, respectively, were isolated by cocultivation with PBMC.PHA. After cultures became positive for HIV-1 p24 antigen, as measured by a commercial ELISA (DuPont/ NEN), they were expanded to 25 ml, and aliquots of cell-free supernatants were stored at -700C. Aliquots from each virus stock, thawed on ice for each experiment, were titered in duplicate by using the limiting dilution method on seronegative donor PBMC.PHA. The rsCD4-blocking titer was established by measuring the lowest concentration of rsCD4 required to inhibit 5 tissue culture infectious dose (TCID) units in duplicate infections of PBMC.PHA.
To produce high-passage HIV-1 isolates, 2.5 x 105 C8166 cells (15) (derived from umbilical cord lymphocytes transformed by human T-cell lymphotropic virus type 1) were cocultured with 1-ml aliquots of each of 20 primary HIV-1 isolates (15 from patient PBMCs and 5 from patient plasmas) in 48-well plates (Costar). After 2 days, cultures were washed three times, and, following addition of R-20 medium, further incubated until the cultures were clearly p24 antigen positive (p24 > 100 pg/ml) and displayed obvious cytopathic effect. Only 7/20 primary isolates (6 from patient PBMCs and 1 from patient plasma) produced measurable p24 and cytopathic effect in this assay. The positive infections were maintained for long-term passage, and clonal virus isolates were produced, as outlined in Fig. 1 . Virus supernatants collected during passage on C8166 cells are named with the letter C followed by the patient identification number and by the number of days in continuous culture with C8166 cells. For example, C-17.44 refers to virus supernatant collected 44 days after initiating C8166 cocultivation with P-17. Primary and C8166-passaged virus isolates were titered on C8166 cells by limiting dilution to determine TCID/ml.
Replication assays to determine the potency of rsCD4 blocking for passaged viruses were carried out across a range of rsCD4 and virus concentrations, as described in Table 2 .
Provirus Sequence Analyses. DNA for polymerase chain reaction (PCR) amplifications was prepared from cells acutely infected with the appropriate virus. Cells, harvested %48 hr after infection, were lysed in Sarkosyl buffer and DNA was extracted as described (16) . Except where noted, PCR was performed according to the supplier's specifications. PCRs were set up with 250 ng of DNA, combined with 25 pmol of each oligonucleotide primer and 1 unit of DNA polymerase (Amplitaq; Perkin-Elmer/Cetus), in a final reaction volume of 100 pAu. All oligonucleotide primers were chosen from the HIVHXB2CG GenBank sequence file, and gpl20 gene amplifications were carried out in two steps by using a model 480 thermal cycler (Perkin-Elmer/Cetus). For gp120 PCR cloning, the first amplification step consisted of30 cycles using oligonucleotide primers REC-07 (5'-ATG-GCAGGAAGAAGCGGAGA-3', coordinates 5969-5988) and REC-09 (5'-AATTGTCTGGCCTGTACCGT-3', coordinates 7835-7854). The second amplification step of 30 cycles used 5% of the product from the first amplification together with primers REC-27 (5'-TAACGGATCCGAGCAGAAGA-CAGTGGCAAT-3', including coordinates 6206-6225 and a 5' sequence that specifies a BamHI site) and REC-12 (5'-
including coordinates 7737-7756 and a 5' sequence that specifies an EcoRI site). The 1550-base-pair (bp) gp120 PCR products were purified by agarose gel electrophoresis prior to digestion with BamHI and EcoRI and cloning. Bulk PCR nucleotide sequence analyses were performed as described (17) (Nunc) .
Expression of r-gpl20 was measured by ELISA. Immulon-2 96-well microtiter plates (Dynatech) were coated overnight at 4°C with rsCD4 (Biogen) at 50 ug/ml in 50 mM Na2CO3, pH 9.6. Plates were blocked with phosphatebuffered saline (PBS)/2% dry milk (Carnation) for 30 Purification of r-gpl20. Forty-eight-hour conditioned media from transiently transfected COS cells were filtered through 0.22-,um-pore filters and stored at -20°C. Four hundred milliliters of each gpl20-containing medium was diluted with 400 ml of PBS and 16 ml of 1 M Tris'HCI, pH 7.7.
Proteins were batch-loaded onto 6 ml of lentil lectin coupled to Sepharose 4B (Pharmacia) in an overnight incubation at 40C with continuous stirring. The gel was collected in a 1-cm-diameter column and washed with PBS, and the total glycoprotein pool was released by treatment with 10%6 N-ace-tylglucosamine/300 mM NaCl/100 mM Tris-HCI, pH 7.7. Fractions were monitored by absorbance at 280 nm and by ELISA (see above). Following concentration of peak fractions, the gpl20s were further purified on a CD4 affinity column that had been prepared by coupling rsCD4 on AffiGel-10 (Bio-Rad) at 10 mg of protein per ml of gel. Then 200
Al of washed CD4 beads was added to the 1.5 ml of concentrate and incubated overnight at 40C. The product was eluted from the gel with 50 mM glycine, pH 3.0/250 mM NaCl and immediately neutralized by adding Hepes, pH 7.5, to 100 mM. Fractions were analyzed by SDS/PAGE and by ELISA. Peak fractions were pooled and stored in aliquots at -700C. The overall yield and fold purification for the two r-gpl2Os were 28% and >59,000 for HIV-1/IIIB and 54% and 38,000 for P-17 gpl20, respectively. rsCD4/gpl2O Affinity Measurements. The affinity of gpl20 for rsCD4 was assessed in an ELISA format (18 HIV-1 isolates produced during this study are preceded by the letter P. The isolation of JR.CSF and JR.FL (13) and the rsCD4 refractoriness of these isolates (10) TCID) and rsCD4 (300, 100, 30, 10, 3, 1, or 0.3 Ag/ml, final concentration) were mixed in triplicate and incubated in 48-well plates for 60 min at 370C prior to the addition of 2.5 x 105 C8166 in R-20. Infection mixtures (total volume 1 ml) were allowed to incubate for 10-14 days, and virus growth was assessed by both the appearance of a cytopathic effect and the production of HIV-1 p24 antigen. ND, not done. p24 values among primary isolates has been previously documented (19) , and it did not appear to be a factor for the degree of rsCD4 resistance (Table 1 ). Because primary virus isolates are refractory to rsCD4, even at limiting dilution (data not shown), it is likely that the resistant population represents the major fraction of virus. Fig. 1 illustrates how patient plasmas or HIV-1 isolates generated from patient PBMCs were utilized to produce high-passage, cell line-adapted HIV-1 isolates.
Primary isolates, in each case, were cultured with CD4' C8166 cells for extended periods, as described in Fig. 1 . When this approach is used, the potency of rsCD4 for blocking virus replication apparently increases dramatically within 6-10 weeks of passage (Table 2) . For example, a primary isolate from the plasma of patient 17 (P-17), which requires rsCD4 at >100 ttg/ml to block replication of 5 TCID in vitro, becomes approximately 100-fold more sensitive to rsCD4 blocking by 75 days of passage (Fig. 2) .
Two possible explanations for this phenomenon are (i) a trans-acting inhibitory factor (e.g., defective interfering particles) abrogates rsCD4 activity and (ii) resistance is due to a host cell-specific factor. The presence of a trans-acting factor only in low-passage patient HIV-1 isolates was tested by mixing an rsCD4-resistant virus isolate (P-0104B) and an rsCD4-sensitive virus isolate (HIV-1/IIIB) prior to titrating against rsCD4 in the C8166 cell replication assay described above. Because P-0104B cannot replicate in the C8166 cell line in our assay, it was possible to measure directly the sensitivity of HIV-1/IIIB in the presence the rsCD4-resistant isolate P-0104B. Replication of the mixed virus inoculum was iden- Proc. Natl. Acad. Sci. USA 89 (1992) tical to HIV-1/IIIB alone, being blocked completely by rsCD4 at <1 ,ug/ml (data not shown). To determine if resistance to rsCD4 blocking is host cell specific, blocking assays with equal amounts of primary and passaged viruses were carried out in PBMC.PHA and C8166, in parallel. In these assays, relative resistance to rsCD4 is roughly equivalent (within a factor of 3), regardless of the host cell (data not shown).
The results described above suggest that during passage in CD4+ cell lines primary virus isolates undergo selection leading to altered interaction with CD4. If affinity between the virus envelope and CD4 increases during passage, nucleotide sequence changes in the gpl20-encoding portion of the virus envelope gene could be responsible. To determine the changes in envelope sequence that occurred during passage of P-17, provirus env genes from pairs of HIV-1 isolates were subjected to DNA sequence analyses using PCR. To address the problem of virus heterogeneity (20) , both "bulk" sequence from the unfractionated PCR product and sequences Fig. 3 . Amino acid coordinates correspond to the gpl20 map in Fig. 3A .
from PCR subclones of gpl20 genes (two from each isolate) were compared. Bulk sequence of the env PCR product should be representative of the predominant (-90%) sequence at any nucleotide position from the total provirus population (R.T., unpublished results). Fig. 3A shows amino acid sequence comparisons deduced from DNA sequence analyses for P-17.14 and C-17.75. As summarized in Table 3 , bulk gpl20 sequence comparisons show that P-17.14 and C-17.75 differ in gpl20 by only one amino acid, while comparison of PCR subclones shows three amino acid heterogeneities, one ofwhich is identical to that found in the bulk sequence analysis. Fig. 3B shows that the three heterogeneities map outside regions previously shown to be involved in CD4 binding (2) .
Sequence analysis of the patient 17 virus shows that acquisition of rsCD4 sensitivity to blocking does not correlate with major changes in the primary structure ofgpl20. To determine whether or not the three gpl20 sequence heterogeneities affect CD4 binding, a direct measurement ofP-17 gpl20/CD4 affinity was performed using P-17 r-gpl20 that was produced in COS cells. As a high-affinity control, r-gpl20 corresponding to that from HIV-1/IIIB was produced in parallel. Affinity purification yielded relatively pure glycoproteins with similar apparent molecular weights, as shown in Fig. 4A . In the gpl20 competition ELISA described in Materials and Methods, P-17-derived gpl20 has an apparent rsCD4 binding affinity not significantly different from that of HIV-1/IIIB gpl20. The competition curves presented in Fig. 4B show that the apparent Kd for both gpl20s is -2 nM, in agreement with previously published measurements (1, 6, 22, 23) .
DISCUSSION
The HIV-1 rsCD4 resistance documented here and elsewhere (10) raises questions about the potential therapeutic utility of rsCD4, a drug candidate that has yielded rather equivocal Table 3 . results in early clinical trials (14, 24) . A key assumption behind CD4-based therapeutic strategies is high-affinity binding between CD4 and virus envelope (1) . Therefore, testing the validity ofthe hypothesis that CD4/patient HIV-1 affinity is much lower than that measured with laboratory HIV-1 could be crucial for defining the appropriate therapeutic setting for CD4 congeners.
By generating matched pairs of virus isolates that differ with regard to in vitro passage number and, correlatively, differ in refractoriness to rsCD4, it has been possible to search for env gene heterogeneities that might account for altered interaction with CD4. The results presented above reveal that the deduced amino acid changes found in gpl20 from HIV-1 P-17, subjected to prolonged passage in vitro, do not occur within regions of gpl20 previously mapped for CD4 interaction (2) . We have subjected a second patient virus isolate pair (P-08/C-08) to the sequence analysis described above, and we have confirmed the results found with P-17/ C-17-i.e., sequence heterogeneity occurs outside regions previously mapped to interact with CD4 (data not presented). Consistent with the nucleotide sequence-comparison, r-gpl20 from the P-17 isolate binds rsCD4 with affinity equivalent to r-gpl20 derived from extensively passaged, rsCD4-sensitive HIV-1/IIIB. This strongly implies that gpl20/rsCD4 affinity does not change during passage of HIV-1 in vitro, although it does not rule out the possibility that virus-associated envelope from primary patient viruses might have lower affinity for CD4. Indeed, CD4 affinity for HIV-1 could be determined by the unique conformation of the gpl20/gp41 heterooligomer that forms the virus envelope spike (23, (25) (26) (27) . No such discrepancy in rsCD4 binding affinity has been found when HIV-1/IIIB and the corresponding r-gpl20 were compared (18), but primary virus envelope-CD4 interactions may not follow this pattern (25, 26) . What is clear from our analysis is that gpl20/CD4 affinity alone does not predict HIV-1 susceptibility to neutralization by rsCD4.
Several recent studies have implicated an unexpected mechanism for rsCD4-mediated HIV-1 neutralization. Experiments with cell line-adapted HIV-1 show that such isolates have differential rates of envelope gp120 shedding (5) that can be greatly enhanced by rsCD4 binding (9, 28) , a phenomenon that could be likened to CD4-induced envelope "stripping." The physiological correlate to this process could be initiating virus entry (25, 26) . If rsCD4 neutralizes laboratory HIV-1 by inducing gpl20 shedding, or "stripping," it is possible that patient HIV-1 is somehow "strip-proof' and therefore not subject to irreversible blocking by CD4-based antiviral agents. If this mechanism accounts, at least in part, for the dramatic shift in rsCD4 sensitivity of primary isolates upon passage, it is likely that gpl20-gp41 interactions are altered during passage in vitro. Interestingly, we find that the gpl20 sequence heterogeneities found by comparing P-17 and C-17 occur within in a region involved in gpl20-gp41 interactions (21) (Fig. 3B) (25, (29) (30) (31) . It will be of interest to define the genetic determinants of HIV-1 rsCD4 resistance.
While this manuscript was being reviewed, two studies (32, 33) independently demonstrated equivalent and high-affinity interactions between CD4 and r-gpl20 from either cell lineadapted or primary HIV-1 isolates. We have extended these observations by comparing r-gpl2Os derived from viruses within a defined lineage.
